1475-P: Effect of Structured Lifestyle Coaching Outcome on Metabolic Syndrome and Metabolic Age in Type 2 Diabetes: A Three-Month Comparative Study

Introduction and Objective: Metabolic syndrome (MetS) clusters led to abnormalities accelerating metabolic aging. This 3-month randomized controlled trial compared the outcomes of MetS score and BCA-derived metabolic age through Sugarfit's Digital lifestyle management program versus standard of care (SOC). Methods: This trial enrolled 149 T2D adults: Test (personalized lifestyle coaching + SOC, n=87) vs Control (SOC alone, n=62). MetS score was assessed per IDF criteria with South Asian-specific cutoffs using waist circumference to define central obesity as a key factor. HbA1c, fasting blood sugar (FBS), weight, blood pressure (BP), triglyceride (TG), and high-density lipoprotein (HDL) were assessed at baseline and 90 days to evaluate lifestyle-based intervention’s impact on glycemic and anthropometric outcomes. Results: MetS prevalence in TG was 71 and CG was 52. At 90 days, the TG showed clear metabolic improvements where the prevalence was decreased to 58 participants, all MetS score combinations declined (BP/FBS: 17.74%, BP/TG: 14.52%, BP/HDL: 16.13%, TG/FBS: 14.52%, TG/HDL: 14.52%, FBS/HDL: 9.68%), metabolic age remained stable (55.94 → 55.91 years), and HbA1c (9.49±1.87→7.84±1.30%), FBS (162.22±56.14→140.97±52.54 mg/dL), weight (75.85±12.86→74.32±12.96 kg) improved. In contrast, MetS prevalence in CG increased to 53 participants with minimal changes in MetS score components, increasing metabolic age (58.60→60.97 years), and rising HbA1c/FBS with negligible anthropometric changes. Conclusion: Digital lifecoach-led personalized guidance in lifestyle management resulted in improved metabolic health, with notable reductions in MetS prevalence and scores. Improvements in glycemia and anthropometry compared with minimal or adverse changes in SOC. Long-term studies on similar platforms and care methods will further support the need for virtual, personalized, precision care in managing metabolic syndrome and its associated complications. Disclosure C.G. Mehra: None. A.M. Raymond: None. A. Sequeira: None. J. Joseline: None. S. Kumar: None.